Overview

Phase 1 Study of CM082 in Patients With wAMD

Status:
Suspended
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD.
Phase:
Phase 1
Details
Lead Sponsor:
AnewPharma
Collaborator:
West China Hospital
Treatments:
Vorolanib